Company intelligence / Profile preview

AG1

Ownership: Public · AG1
Development stage: Commercial

Overview

AG1’s flagship product is a daily health drink clinically shown to improve key nutrient biomarkers (e.g., RBC folate and vitamin C), enrich the gut microbiome with healthy bacteria, and close common nutrient gaps. These results are supported by multiple randomized placebo-controlled clinical trials in healthy adults. The latest formula ("AG1 Next Gen") includes five clinically studied probiotic strains and an enhanced methylated B complex.

Modalities: MultivitaminProbioticPrebioticAdaptogen blend
Industry: Food & Nutrition

Drug pipeline

1 asset

AG1

Commercial

Indications: Daily nutrition supplementation

Partnerships

Costco – retail distribution partnership announced May 2025 for nationwide US availability.

Financials

Market cap: $1.6B
Total revenue: $3.3B
Enterprise value: $11.2B

Beyond the preview

Go deeper on AG1.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG1.

Explore the full profile